ONCAlert | 2018 ASCO Annual Meeting
Videos  >  

Dr. Robin Jones on Olaratumab and Doxorubicin Combination in Patients with Soft Tissue Sarcoma

Robin Jones,BSc, MB, MRCP, MD
Published Online:5:29 PM, Fri December 4, 2015


Robin Jones, BSc, MB, MRCP, MD, oncologist, Royal Marsden Hospital, London, discusses the effectiveness of monoclonal antibody olaratumab in combination with doxorubicin in metastatic soft tissue sarcoma. The treatment was tested in a phase II trial, which randomized patients to either receive doxorubicin alone or doxorubicin in combination with olaratumab.


Jones says there was a significant difference in median overall survival in patients who received doxorubicin in combination with olaratumab compared to the monotherapy. He adds that patients had a median overall survival of 25 months in the combination arm, versus a median overall survival of 14.7 months in the doxorubicin alone arm.

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.